Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

Dicerna and Novo Nordisk to discover and develop RNAi therapies for liver-related cardio-metabolic diseases. Photo: courtesy of Novo Nordisk A/S.